Management of Dyspnea at the End of Life
Assessment and Initial Approach
- The National Comprehensive Cancer Network recommends regularly assessing patients with serious illness at the end of life for dyspnea, as it is one of the most distressing symptoms experienced by dying patients 1
- For non-communicative patients, physical signs of respiratory distress such as labored breathing can be used as indicators of potential dyspnea 3, 4
- Determining the estimated life expectancy is crucial to guide appropriate intervention strategies, with considerations for years, months to weeks, or weeks to days 3, 5
Treatment Algorithm Based on Life Expectancy
- For patients with years of life expectancy, the National Comprehensive Cancer Network suggests treating underlying causes and comorbid conditions, including consideration of radiation/chemotherapy for malignancies, therapeutic procedures for cardiac, pleural, or abdominal fluid, and use of bronchoscopic therapy, bronchodilators, diuretics, steroids, antibiotics, or transfusions as indicated 3
- The American College of Physicians recommends providing symptomatic relief, including oxygen therapy for patients with hypoxemia or those reporting subjective relief, and nonpharmacologic interventions such as fans, cooler temperatures, stress management, and relaxation therapy 3, 4
- For patients with months to weeks of life expectancy, the National Comprehensive Cancer Network recommends administering morphine 2.5-10 mg PO every 2 hours as needed or 1-3 mg IV every 2 hours as needed for opioid-naive patients, and considering increasing the dose by 25% for those already on chronic opioids 3, 5, 6
- Benzodiazepines can be added for dyspnea associated with anxiety, starting with lorazepam 0.5-1 mg PO every 4 hours as needed 3
- Noninvasive positive-pressure ventilation (CPAP, BiPAP) can be considered for severe reversible conditions 3
- For fluid overload, decreasing or discontinuing enteral or parenteral fluid and considering low-dose diuretics can be beneficial 5, 6
- Excessive secretions can be managed with scopolamine 0.4 mg subcutaneous every 4 hours as needed or 1.5 mg patches (1-3 patches every 3 days), or alternative options such as atropine 1% ophthalmic solution or glycopyrrolate 0.2-0.4 mg IV or subcutaneous every 4 hours as needed 5, 4, 6
Special Considerations
- For acute progressive dyspnea, more aggressive opioid titration may be required 3, 4
- Undertreatment of dyspnea due to concerns about respiratory depression from opioids is a common pitfall, but evidence supports their safety and efficacy when appropriately dosed 1, 2
- Overreliance on oxygen therapy in non-hypoxemic patients can be ineffective, and failure to address psychological and emotional components of dyspnea can amplify the symptom 4
- Delaying palliative interventions until the very end of life can reduce quality of life, and early implementation of symptom management strategies is recommended 1